Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections (Nov, 10.1093/cid/ciz1131, 2019)

Shields R. K.; McCreary E. K.; Marini R. V

首页> 外文期刊>Clinical infectious diseases >Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections (Nov, 10.1093/cid/ciz1131, 2019)

【24h】

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections (Nov, 10.1093/cid/ciz1131, 2019)

机译：早期经验与Meropenem-VaborbAdAcAM用于治疗CarbapeNem抗性肠杆菌痤疮感染（11月，10.1093 / CID / CIZ1131,2019）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical infectious diseases 》 |2020年第6期| 共1页
作者
Shields R. K.; McCreary E. K.; Marini R. V;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections (Nov, 10.1093/cid/ciz1131, 2019) [J] . Shields R. K., McCreary E. K., Marini R. V Clinical infectious diseases . 2020 ,第6期

机译：早期经验与Meropenem-VaborbAdAcAM用于治疗CarbapeNem抗性肠杆菌痤疮感染（11月，10.1093 / CID / CIZ1131,2019）
2. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae [J] . Sabet Mojgan, Tarazi Ziad, Nolan Thomas, Antimicrobial agents and chemotherapy. . 2018 ,第1期

机译：KPC生产肠杆菌肠杆菌基孢菌肠杆菌肠杆菌肠杆菌肠杆菌肠杆菌肠道模型中梅洛涅姆-VabbordActam的活性
3. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae [J] . Lindsay A Petty, Oryan Henig, Twisha S Patel, Infection and Drug Resistance . 2018 ,第9期

机译：美罗培南-vaborbactam和新型抗微生物剂治疗耐碳青霉烯的肠杆菌科细菌概述
4. EFFECTS OF WATER TREATMENT TECHNOLOGY AND UV DISINFECTION ON NOM FRACTIONS AND BDOC: EXPERIENCES FROM FULL-SCALE FACILITIES IN NORWAY [C] . Bjomar Eikebrokk Disinfection By-products in Drinking Water Conference . 2016

机译：水处理技术与UV消毒对NOM分数和BDOC的影响：挪威全规模设施的经验
5. Is targeted testing and treatment for latent tuberculosis infection cost-effective? The experience of Tennessee. [D] . Ferroussier-Davis, Odile. 2014

机译：对潜伏性结核感染进行有针对性的测试和治疗是否具有成本效益？田纳西州的经验。
6. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections [O] . Renee Ackley, Danya Roshdy, Jacqueline Meredith, 2020

机译：Meropenem-vaborbatam与Ceftazidime-Avibactam进行治疗Carbapenem型肠杆菌菌感染
7. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections [O] . Renee Ackley, Danya Roshdy, Jacqueline Meredith, 2020

机译：Meropenem-vaborbatam与Ceftazidime-Avibactam进行治疗Carbapenem型肠杆菌菌感染
8. Multidrug-Resistant Gram-Negative Bacterial and Carbapenem-Resistant Enterobacteriaceae Infections in the Department of the Navy: Annual Report 2013. [R] . Meddaugh, P., Chukwuma, U. 2015

机译：海军部多重抗药性革兰氏阴性细菌和耐碳青霉烯类肠杆菌感染：2013年年度报告。

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections (Nov, 10.1093/cid/ciz1131, 2019)

著录项

相似文献

相关主题

期刊订阅